CA2416456A1 - Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides - Google Patents

Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides Download PDF

Info

Publication number
CA2416456A1
CA2416456A1 CA002416456A CA2416456A CA2416456A1 CA 2416456 A1 CA2416456 A1 CA 2416456A1 CA 002416456 A CA002416456 A CA 002416456A CA 2416456 A CA2416456 A CA 2416456A CA 2416456 A1 CA2416456 A1 CA 2416456A1
Authority
CA
Canada
Prior art keywords
seq
acid sequence
amino acid
pro
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002416456A
Other languages
English (en)
Inventor
Kevin P. Baker
Luc Desnoyers
Mary E. Gerritsen
Audrey Goddard
Paul J. Godowski
J. Christopher Grimaldi
Austin L. Gurney
Victoria Smith
Jean-Philippe F. Stephan
Colin K. Watanabe
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/fr
Priority claimed from PCT/US2000/023522 external-priority patent/WO2001016319A2/fr
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/fr
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/fr
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/fr
Priority claimed from US09/747,259 external-priority patent/US6569645B2/en
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/fr
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/fr
Priority claimed from PCT/US2001/006666 external-priority patent/WO2001066740A2/fr
Priority claimed from US09/816,744 external-priority patent/US6579520B2/en
Priority claimed from US09/854,208 external-priority patent/US7217412B2/en
Priority claimed from PCT/US2001/017092 external-priority patent/WO2001092331A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2416456A1 publication Critical patent/CA2416456A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention se rapporte à de nouveaux polypeptides et à des molécules d'acide nucléique codant ces polypeptides. Cette invention concerne également des vecteurs et des cellules hôtes comprenant ces séquences d'acide nucléique, des molécules de polypeptide chimérique comprenant ces polypeptides fusionnés à des séquences de polypeptides hétérologues, des anticorps qui se fixent à ces polypeptides et des procédés destinés à produire ces polypeptides.
CA002416456A 2000-07-20 2001-06-29 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides Abandoned CA2416456A1 (fr)

Applications Claiming Priority (52)

Application Number Priority Date Filing Date Title
US21955600P 2000-07-20 2000-07-20
US60/219,556 2000-07-20
US22066400P 2000-07-25 2000-07-25
US22063800P 2000-07-25 2000-07-25
US22066600P 2000-07-25 2000-07-25
US22060700P 2000-07-25 2000-07-25
US22062400P 2000-07-25 2000-07-25
US22058500P 2000-07-25 2000-07-25
US22060500P 2000-07-25 2000-07-25
US60/220,666 2000-07-25
US60/220,585 2000-07-25
US60/220,664 2000-07-25
US60/220,638 2000-07-25
US60/220,607 2000-07-25
US60/220,605 2000-07-25
US60/220,624 2000-07-25
US22089300P 2000-07-26 2000-07-26
US60/220,893 2000-07-26
PCT/US2000/020710 WO2001009327A2 (fr) 1999-07-28 2000-07-28 Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
USPCT/US00/20710 2000-07-28
US22242500P 2000-08-01 2000-08-01
US60/222,425 2000-08-01
US22713300P 2000-08-22 2000-08-22
US60/227,133 2000-08-22
USPCT/US00/23522 2000-08-23
PCT/US2000/023522 WO2001016319A2 (fr) 1999-08-31 2000-08-23 Compositions et procedes pour le traitement de maladies d'ordre immunologique
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
USPCT/US00/23328 2000-08-24
US60/000,000 2000-09-15
PCT/US2000/030873 WO2001040465A2 (fr) 1999-11-30 2000-11-10 Compositions et procedes de traitement de maladies d'ordre immunologique
USPCT/US00/30873 2000-11-10
US25364600P 2000-11-28 2000-11-28
US60/253,646 2000-11-28
USPCT/US00/32678 2000-12-01
PCT/US2000/032678 WO2001040466A2 (fr) 1999-12-01 2000-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
US09/747,259 2000-12-20
US09/747,259 US6569645B2 (en) 1999-05-14 2000-12-20 IL-17 homologous polypeptides and therapeutic uses thereof
PCT/US2000/034956 WO2001046420A2 (fr) 1999-12-23 2000-12-20 Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
USPCT/US00/34956 2000-12-20
PCT/US2001/006520 WO2001068848A2 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US01/06520 2001-02-28
USPCT/US01/06666 2001-03-01
PCT/US2001/006666 WO2001066740A2 (fr) 2000-03-03 2001-03-01 Compositions et methodes de traitement de maladies d'origine immune
US09/816,744 US6579520B2 (en) 1998-05-15 2001-03-22 IL-17 related mammalian cytokine polypeptides (IL-17E)
US09/816,744 2001-03-22
US09/854,208 US7217412B2 (en) 1998-05-15 2001-05-10 IL-17C related mammalian cytokine polypeptides
US09/854,280 2001-05-10
US09/854,208 2001-05-10
US09/854,280 US7115398B2 (en) 1998-05-15 2001-05-10 IL-17 homologous polypeptides and therapeutic uses thereof
USPCT/US01/17092 2001-05-25
PCT/US2001/017092 WO2001092331A2 (fr) 2000-05-30 2001-05-25 Compositions et methodes de traitement de maladies d'origine immune
PCT/US2001/021066 WO2002008288A2 (fr) 2000-07-20 2001-06-29 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides

Publications (1)

Publication Number Publication Date
CA2416456A1 true CA2416456A1 (fr) 2002-01-31

Family

ID=56290161

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002416456A Abandoned CA2416456A1 (fr) 2000-07-20 2001-06-29 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides

Country Status (5)

Country Link
EP (1) EP1354040A2 (fr)
JP (1) JP2004514420A (fr)
AU (2) AU2001273150A1 (fr)
CA (1) CA2416456A1 (fr)
WO (1) WO2002008288A2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU738688B2 (en) 1997-09-12 2001-09-27 Apoxis Sa Cysteine rich receptors-train
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
US20030232056A1 (en) 1999-09-10 2003-12-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1897945B1 (fr) * 1999-12-23 2012-01-18 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1700867A3 (fr) * 2000-06-02 2006-09-20 Genentech, Inc. Polypeptide secrétée et transmembranaire, ainsi que les acides nucléiques qui les codent
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
US20030017572A1 (en) * 2000-09-25 2003-01-23 Rajasekhar Bandaru 56294 and 56629, novel human metalloproteases and uses thereof
EP1325029A2 (fr) * 2000-09-28 2003-07-09 Eli Lilly And Company Nouvelles proteines secretees et utilisations de ces dernieres
AU2002230778A1 (en) 2000-11-03 2002-05-15 The Regents Of The University Of California Prokineticin polypeptides, related compositions and methods
AU2002226079A1 (en) 2000-12-08 2002-06-18 Curagen Corporation Method of detecting and treating tuberous sclerosis complex associated disorders
DE10106835A1 (de) * 2001-02-14 2002-09-05 Basf Lynx Bioscience Ag Signaltransduktionsproteine 15B3, 15B3-1 und 15B3-2 und zugrundeliegende DNA-Sequenzen
GB2378183A (en) * 2001-04-25 2003-02-05 Smithkline Beecham Corp Assays of the interaction between AXOR8 or AXOR52 and BV-8 ligand
CA2446610A1 (fr) * 2001-06-06 2002-12-12 Human Genome Sciences, Inc. 20 proteines humaines secretees
US20030120040A1 (en) 2001-06-29 2003-06-26 Genentech, Inc. Secreted and Transmembrane polypeptides and nucleic acids encoding the same
SI2230299T1 (sl) 2002-01-18 2012-07-31 Zymogenetics Inc Nov citokinski zcytor ligand
MXPA04010092A (es) * 2002-04-16 2004-12-13 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
US7141381B2 (en) 2002-04-25 2006-11-28 Bristol-Myers Squibb Company Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
EP1416279B1 (fr) * 2002-10-31 2008-12-31 F. Hoffmann-La Roche Ag Methodes et compositions pour le diagnostic du cancer du pancreas
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1573048A4 (fr) * 2002-12-20 2007-02-14 Avalon Pharmaceuticals Proteine specifique du sein exprimee dans le cancer, et ses methodes d'utilisation
EP2526960A1 (fr) 2003-03-12 2012-11-28 Genentech, Inc. Utilisation de BV8 et/ou de EG-VEGF pour promouvoir l'hématopoièse
EP1617802A4 (fr) * 2003-04-30 2007-08-01 Centocor Inc Polynucleotides specifiques de cngh0010, polypeptides, anticorps, compositions, methodes et utilisations
US7479479B2 (en) 2003-04-30 2009-01-20 Centocor, Inc. CNGH0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses
EP1503212B1 (fr) * 2003-07-28 2007-05-23 F. Hoffmann-La Roche Ag Méthode de diagnostic de métastases, thérapie et composition utile à cela
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US20070259383A1 (en) * 2004-03-02 2007-11-08 Eisal R&D Management Co., Ltd Novel Genes involved in Epidermal differentiation, and uses thereof
CA2572239C (fr) 2004-06-24 2019-07-09 Mayo Foundation For Medical Education And Research Polypeptide costimulant b7-h5
JP2008505182A (ja) 2004-07-02 2008-02-21 ジェネンテック・インコーポレーテッド 非ホジキンリンパ腫の治療のための組成物と方法
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
JP5065253B2 (ja) 2005-05-06 2012-10-31 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１モノクローナル抗体とその使用法
AU2007254715B2 (en) 2005-05-06 2013-08-29 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
EP2049518B1 (fr) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Derives de l'indazole et de l'isoindazole comme agents de l'activation de glucokinase
EP2091947A2 (fr) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Activateurs de glucokinase
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
ME03057B (fr) 2007-12-07 2019-01-20 Zymogenetics Inc Molécules d'anticorps humanisés spécifiques pour l'IL-31
KR20110025649A (ko) 2008-05-05 2011-03-10 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
US9809815B2 (en) 2009-02-20 2017-11-07 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
RU2605318C2 (ru) 2009-05-05 2016-12-20 Новиммун С.А. Анти-il-17f антитела и способы их применения
CA2775373C (fr) 2009-11-11 2019-10-29 Ganymed Pharmaceuticals Ag Anticorps specifiques pour la claudine 6 (cldn6)
EP2404936A1 (fr) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
CN107090043B (zh) 2011-05-13 2021-12-07 加尼梅德药物公司 用于治疗表达密蛋白6之癌症的抗体
US9848543B2 (en) 2013-07-09 2017-12-26 E I Du Pont De Nemours And Company System and method for irrigation
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
GB201810301D0 (en) * 2018-06-22 2018-08-08 Evox Therapeutics Ltd Combinatorial gene therapy
CN111848792B (zh) * 2020-07-16 2023-02-24 浙江省食品药品检验研究院 疫苗中牛血清白蛋白等杂质的抗体制备方法及检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US6060249A (en) * 1997-02-27 2000-05-09 Genentech, Inc. Method of selection for genes encoding secreted and transmembrane proteins
AU3753499A (en) * 1998-04-20 1999-11-08 Paul B. Fisher Colon cancer-associated antigens and their diagnostic and therapeutic uses
EP1263948A2 (fr) * 1999-03-08 2002-12-11 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA2361277A1 (fr) * 1999-03-12 2000-09-21 Craig A. Rosen Proteines humaines secretees (49)
EP1208195A2 (fr) * 1999-06-15 2002-05-29 Genentech Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
WO2001055355A1 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same

Also Published As

Publication number Publication date
EP1354040A2 (fr) 2003-10-22
AU7315001A (en) 2002-01-30
WO2002008288A3 (fr) 2003-08-14
AU2001273150A1 (en) 2002-02-05
WO2002008288A2 (fr) 2002-01-31
JP2004514420A (ja) 2004-05-20

Similar Documents

Publication Publication Date Title
US20030092887A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2416456A1 (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
CA2410162A1 (fr) Polypeptide pro 4332 marqueur de tumeurs du poumon, du colon, du rectum et du sein et acide nucleique codant pour ce polypeptide
US20030096969A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030100725A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030100715A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030187212A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030100713A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030100709A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030187218A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030149239A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030187215A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030092890A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030187214A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030096965A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030100708A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued